Beyond its role in the stimulation of cGMP action, recent studies have demonstrated that PDE5 inhibitors decrease the activation of SSc fibroblasts by counteracting ROS effects and inhibiting the production of pro-inflammatory cytokines (Di Luigi et al. 2020; Antinozzi et al. 2021). The gene discussed is PDE5A; the disease is systemic sclerosis.